DECR1 and prostate neoplasm: CSNK2A2 has been reported as a marker of PCa progression and prognosis [46], while DECR1 acts as an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis [47].